课题基金 / 基金详情

A novel anti-angiogenic therapy for endometriosis

A novel anti-angiogenic therapy for endometriosis
子宫内膜异位症的新型抗血管生成疗法
批准号：
224980
负责人：
Tayade Chandrakant
金额：
$35.22万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2011
资助国家：
加拿大
项目状态：
已结题
起止时间：
2011-03-01 至 2016-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=224980&lang=en
关键词：
Angiogenesis Anti-Angiogenic Therapy Chemokines Cytokines Endometriosis Endothelial Progenitor Cells Haematopoietic Progenitor Cells Immunodeficient Mice Laser Capture Microdissection Stromal Cell Derived Growth Factor

项目摘要

项目成果

Tayade Chandrakant的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Endometriosis is characterized by the growth of endometrial tissue (normal uterine lining) outside of the uterus. It affects more than 8.5 million women and teens in North America alone, with 176 million more worldwide. The disease can only be diagnosed
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Unique extracellular vesicle signatures in the pathophysiology of endometriosis
Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting
Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting.
Investigating the role of endocannabinoids in endometriosis pathophysiology and determine efficacy of cannabinoids as a novel therapeutic modality.
海外基金